Trial intelligence / Profile preview

Stapokibart in Adolescent Patients With Seasonal Allergic Rhinitis

NCT07617324Phase 2Not yet recruiting

Sponsor
Chengdu Kangnuoxing Biopharma, Inc.
Start
Jun 2026
Primary completion
Oct 2026
Countries
1
01

Overview

A Phase 2 trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Chengdu Kangnuoxing Biopharma, Inc.. Planned start Jun 2026; status: not yet recruiting.

02

Drugs

stapokibart
03

Conditions

seasonal allergic rhinitis (SAR)

Beyond the preview

Go deeper on NCT07617324.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07617324.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call